Efficacy of early intravenous high-dose vitamin C in post-cardiac arrest shock: a multicenter, randomized controled to standard treatment, open label trial. - VICEPAC

Centre Hospitalier Bethune Beuvry0 个研究点目标入组 234 人开始时间: 2022年12月14日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•patients still comatose (Glasgow coma scale < 8), an OHCA of presumed cardiac origin with ROSC < 60 min, treated with a norepinephrin or an epinephrin continuous infusion = 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) = 65 mmHg.

•minor, pre-existent severe chronic kidney disease (glomerular filtration rate < 30ml/min), moribound or chronic disease (life expectancy <1 an)., Patient with legal protective measures, Patient not covered by French national health insurance, known vit-C deficit, Patient with derpived freedom, Hyperoxaluria, Hystory of urolithiasis, pregnant women, OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc..), interval between OHCA and randomization > 4 hours, extracorporeal circulatory assistance requirement in the first 4 hours after OHCA, Hypersensitivity of active substance or méthyl parahydroxybenzoate or dipropyl, Contraindication to vitamine C (glucose-6-phosphate deshydrogenase deficiency; hemochromatosis), patients already treated with vit-C;, inclusion in another interventional study in cardiac arrest or post CA

发起方

Centre Hospitalier Bethune Beuvry